Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01713959 · ClinicalTrials.gov registry record · NA
Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis
A NA study of Hyperhidrosis, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01713959: Completed NA study of Hyperhidrosis, sponsored by Ulthera.
NCT01713959 is a NA study of Hyperhidrosis that has completed, run by Ulthera. The registered enrollment target is 15 participants, below the 97-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01713959, a NA study of Hyperhidrosis, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-center, randomized, split-body, pilot study, treatment of up to 23 subjects in two treatment groups. Subjects will receive two Ultherapy treatments at Day 0 with follow-ups at 7 and 14 days post-treatment #1, and Day 28 with follow-ups are 7, 14, 30, 60, 90 days post-treatment #2.
Primary Outcome
Axillary hyperhidrosis as assessed by using a gravimetric method.
Conditions Studied
Interventions
- DEVICE Sham treatment
- DEVICE Ulthera System treatment
Study Locations (1)
Florida
- The Center for Clinical & Cosmetic Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT01713959 record still lists
NCT01713959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 97-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which Sham treatment is the first listed.
NCT01713959 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01713959 about?
NCT01713959 is a clinical study titled "Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis". Single-center, randomized, split-body, pilot study, treatment of up to 23 subjects in two treatment groups. Subjects will receive two Ultherapy treatments at Day 0 with follow-ups at 7 and 14 days post-treatment #1, and Day 28 with follow-ups are 7, 14, 30, 60, 90 days post-treatment #2.
What is the current status of trial NCT01713959?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2011-08. Estimated completion is 2012-06.
What conditions does trial NCT01713959 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT01713959?
The interventions under investigation include: Sham treatment (DEVICE), Ulthera System treatment (DEVICE).
Who is sponsoring clinical trial NCT01713959?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01713959 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01713959's enrollment target sits among peer trials
15 9th of 8 the lowest of 8 other Hyperhidrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperhidrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
-
Hyperhidrosis in Patients With Amputations-Botox
COMPLETED · Phase 1
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia